Patents Assigned to INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY AS CR V.V.I.
  • Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
    Patent number: 11932664
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: March 19, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Prodrugs of hydroxamate-based GCPII inhibitors
    Patent number: 11866394
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 9, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Mebendazole prodrugs with enhanced solubility and oral bioavailability
    Patent number: 11712435
    Abstract: Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: August 1, 2023
    Assignees: THE JOHNS HOPKINS UNIVERSITY, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Gregory Riggins, Pavel Majer, Tomas Tichy, Jan Vavra, Andrej Jancarik, Lukas Tenora
  • Quinazoline compounds
    Patent number: 10548898
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: February 4, 2020
    Assignees: Gilead Sciences Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Quinazoline compounds
    Patent number: 10206926
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: February 19, 2019
    Assignees: Gilead Sciences, Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
    Patent number: 9988407
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 5, 2018
    Assignees: THE JOHNS HOPKINS UNIVERSITY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Quinazoline compounds
    Patent number: 9730936
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 15, 2017
    Assignees: Gilead Sciences, Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ond{hacek over (r)}ej Baszczy{hacek over (n)}ski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr {hacek over (S)}imon
  • PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR
    Publication number: 20170226141
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Application
    Filed: August 6, 2015
    Publication date: August 10, 2017
    Applicants: The Johns Hopkins University, Institute of Organic Chemistry and Biochemistry as Cr v.v.i.
    Inventors: Barbara SLUSHER, Rana RAIS, Marcela KRECMEROVA, Tomas TICHY, Pavel MAJER, Andrej JANCARIK
  • Fused pyrimidine compounds
    Patent number: 9701677
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: July 11, 2017
    Assignees: Gilead Sciences, Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Petr Jansa, Miroslav Kvasnica, Richard L. Mackman